TITLE PAGE

**Title of the manuscript:**

* Bold face,
* UPPER CASE
* Times new roman,
* Font size 12pt
* **Bold face,**
* **UPPER CASE**
* **Times new roman,**
* **Font size 12pt**

 1 cm from all sides in whole manuscrip

Type of Article: Research Article

Aaaaaa aaaaaaaaa aaaaaa aaaaaaaa aaaaaaaa aaaaa aaaaaa aaaaaaa aaaaaaaaaaaa aaaaaaaaaaaaaa aaaaaaa (Sentence case)

James Z. Miller1\*, Levi C. Canter1, Mackie Y. Honda2

## Authors Name:

* Asterik (\*) in superscript on corresponding author.
* Times New Roman
* Superscripts: indicating designation and
affiliations of the author/co-author
* Lower Case
* Font: 12pt

1Department of Medicine, Rajshahi Medical College, Rajshahi, Bangladesh

2Department of Pharmacology, Rajshahi Medical College, Rajshahi, Bangladesh

**Designation & Affiliation of author/coauthor(s):**• Superscripts: indicating
designation and affiliations of the
author/co-author.
• Times New Roman
• Lower Case
• Font: 12pt

\*Corresponding author:

Dr. James Z. Miller

Department of Medicine,

Rajshahi Medical College, Rajshahi, Bangladesh

ORCID ID: xxxx-xxxx-xxxx

Phone (or Mobile) No.: +xxx-(xxx) xxx-xxxx

Email: xxxxxxxx@xxxxxx.xxx

**For all Sub-headings:**• Times New Roman
• Bold
• UPPER CASE
• Font size: 12 pt

• Font: 12pt

ABSTRACT

Background: Aaaaaa aaaaaaaaa aaaaaa aaaaaaaa aaaaaaaa aaaaa aaaaaa aaaaaaa aaaaaaaaaaaa aaaaaaaaaaaaaa aaaaaaa aaaaaaaaaa aaaaa.

Methods: Aaaaaa aaaaaaaaa aaaaaa aaaaaaaa aaaaaaaa aaaaa aaaaaa aaaaaaa aaaaaaaaaaaa aaaaaaaaaaaaaa aaaaaaa aaaaaaaaaa aaaaa aaaaaaaaaaa aaaaaaaaaaaaa aaaaaaaa aaaaa.

* Structured
* Times New Roman
* <250 words
* 1.5 spacing
* Font: 12 pt font

Results: Aaaaaa aaaaaaaaa aaaaaa aaaaaaaa aaaaaaaa aaaaa aaaaaa aaaaaaa aaaaaaaaaaaa aaaaaaaaaaaaaa aaaaaaa aaaaaaaaaa aaaaa aaaaaaaaaaa aaaaaaaaaaaaa aaaaaaaa aaaaa.

Conclusions: Aaaaaa aaaaaaaaa aaaaaa aaaaaaaa aaaaaaaa aaaaa aaaaaa aaaaaaa aaaaaaaaaaaa aaaaaaaaaaaaaa aaaaaaa aaaaaaaaaa aaaaa aaaaaaaaaaa aaaaaaaaaaaaa.

**Keywords:**• Alphabetical Order
• Limit: 3-5

**Keywords**: Aaaaaa, Aaaaaaaaa, Aaaaaa, Aaaaaaaa

**Abbreviations:**

|  |
| --- |
| **Article at a glance** |
| Study purpose :Key findings :Newer findings added to what is known: | Aaaaa aaaaaAaaaaaa aaaAaaaa aaaaaa |

* Times New Roman
* 1.5 spacing
* Font: 12 pt font

INTRODUCTION

Aaaaaa aaaaaaaaa aaaaaa aaaaaaaa aaaaaaaa aaaaa aaaaaa aaaaaaa aaaaaaaaaaaa aaaaaaaaaaaaaa aaaaaaa aaaaaaaaaa aaaaa. Aaaaaa aaaaaaaaa aaaaaa aaaaaaaa aaaaaaaa aaaaa aaaaaa aaaaaaa aaaaaaaaaaaa aaaaaaaaaaaaaa aaaaaaa aaaaaaaaaa aaaaa. Aaaaaa aaaaaaaaa aaaaaa aaaaaaaa aaaaaaaa aaaaa aaaaaa aaaaaaa aaaaaaaaaaaa aaaaaaaaaaaaaa aaaaaaa aaaaaaaaaa aaaaa.1 Aaaaaa aaaaaaaaa aaaaaa aaaaaaaa aaaaaaaa aaaaa aaaaaa aaaaaaa aaaaaaaaaaaa aaaaaaaaaaaaaa aaaaaaa aaaaaaaaaa aaaaa.2

* Superscript
• References of the literature cited
in the manuscript should be
adequately numbered as in the
reference subheading.

Aaaaaa aaaaaaaaa aaaaaa aaaaaaaa aaaaaaaa aaaaa aaaaaa aaaaaaa aaaaaaaaaaaa aaaaaaaaaaaaaa aaaaaaa aaaaaaaaaa aaaaa. Aaaaaa aaaaaaaaa aaaaaa aaaaaaaa aaaaaaaa aaaaa aaaaaa aaaaaaa aaaaaaaaaaaa aaaaaaaaaaaaaa aaaaaaa aaaaaaaaaa aaaaa.3 Aaaaaa aaaaaaaaa aaaaaa aaaaaaaa aaaaaaaa aaaaa aaaaaa aaaaaaa aaaaaaaaaaaa aaaaaaaaaaaaaa aaaaaaa aaaaaaaaaa aaaaa. Aaaaaa aaaaaaaaa aaaaaa aaaaaaaa aaaaaaaa aaaaa aaaaaa aaaaaaa aaaaaaaaaaaa aaaaaaaaaaaaaa aaaaaaa aaaaaaaaaa aaaaa. Aaaaaa aaaaaaaaa aaaaaa aaaaaaaa aaaaaaaa aaaaa aaaaaa aaaaaaa aaaaaaaaaaaa aaaaaaaaaaaaaa aaaaaaa aaaaaaaaaa aaaaa.4

METHODS

Aaaaaa aaaaaaaaa aaaaaa aaaaaaaa aaaaaaaa aaaaa aaaaaa aaaaaaa aaaaaaaaaaaa aaaaaaaaaaaaaa aaaaaaa aaaaaaaaaa aaaaa. Aaaaaa aaaaaaaaa aaaaaa aaaaaaaa aaaaaaaa aaaaa aaaaaa aaaaaaa aaaaaaaaaaaa aaaaaaaaaaaaaa aaaaaaa aaaaaaaaaa aaaaa. Aaaaaa aaaaaaaaa aaaaaa aaaaaaaa aaaaaaaa aaaaa aaaaaa aaaaaaa aaaaaaaaaaaa aaaaaaaaaaaaaa aaaaaaa aaaaaaaaaa aaaaa. Aaaaaa aaaaaaaaa aaaaaa aaaaaaaa aaaaaaaa aaaaa aaaaaa aaaaaaa aaaaaaaaaaaa aaaaaaaaaaaaaa aaaaaaa aaaaaaaaaa aaaaa.

Aaaaaa aaaaaaaaa aaaaaa aaaaaaaa aaaaaaaa aaaaa aaaaaa aaaaaaa aaaaaaaaaaaa aaaaaaaaaaaaaa aaaaaaa aaaaaaaaaa aaaaa. Aaaaaa aaaaaaaaa aaaaaa aaaaaaaa aaaaaaaa aaaaa aaaaaa aaaaaaa aaaaaaaaaaaa aaaaaaaaaaaaaa aaaaaaa aaaaaaaaaa aaaaa. Aaaaaa aaaaaaaaa aaaaaa aaaaaaaa aaaaaaaa aaaaa aaaaaa aaaaaaa aaaaaaaaaaaa aaaaaaaaaaaaaa aaaaaaa aaaaaaaaaa aaaaa. Aaaaaa aaaaaaaaa aaaaaa aaaaaaaa aaaaaaaa aaaaa aaaaaa aaaaaaa aaaaaaaaaaaa aaaaaaaaaaaaaa aaaaaaa aaaaaaaaaa aaaaa.

**Table:**

* Bold
* Font: 12 pt

RESULT

**Table 1:**aaaaaaaaaaaaa aaaaaaaaaaa aaaaaaaaaaaa aaaaaaaaaaaa aaaaaaaa.

|  |  |  |
| --- | --- | --- |
| **Aaaaaaaa** | **aaaaaa (n)** | **aaaaa (%)** |
| **Aaaa** | **Aaa** |  |  |
| **X** | **X** | X | X |
| **X** | **X** | X | X |
| **X** | **X** | X | X |
| **X** | **X** | X | X |

Aaaaaa aaaaaaaaa aaaaaa aaaaaaaa aaaaaaaa aaaaa aaaaaa aaaaaaa aaaaaaaaaaaa aaaaaaaaaaaaaa aaaaaaa aaaaaaaaaa aaaaa. Aaaaaa aaaaaaaaa aaaaaa aaaaaaaa aaaaaaaa aaaaa aaaaaa aaaaaaa aaaaaaaaaaaa aaaaaaaaaaaaaa aaaaaaa aaaaaaaaaa aaaaa. Aaaaaa aaaaaaaaa aaaaaa aaaaaaaa aaaaaaaa aaaaa aaaaaa aaaaaaa aaaaaaaaaaaa aaaaaaaaaaaaaa aaaaaaa aaaaaaaaaa aaaaa. Aaaaaa aaaaaaaaa aaaaaa aaaaaaaa aaaaaaaa aaaaa aaaaaa aaaaaaa aaaaaaaaaaaa aaaaaaaaaaaaaa aaaaaaa aaaaaaaaaa aaaaa (Table 1).

Aaaaaa aaaaaaaaa aaaaaa aaaaaaaa aaaaaaaa aaaaa aaaaaa aaaaaaa aaaaaaaaaaaa aaaaaaaaaaaaaa aaaaaaa aaaaaaaaaa aaaaa. Aaaaaa aaaaaaaaa aaaaaa aaaaaaaa aaaaaaaa aaaaa aaaaaa aaaaaaa aaaaaaaaaaaa aaaaaaaaaaaaaa aaaaaaa aaaaaaaaaa aaaaa. Aaaaaa aaaaaaaaa aaaaaa aaaaaaaa aaaaaaaa aaaaa aaaaaa aaaaaaa aaaaaaaaaaaa aaaaaaaaaaaaaa aaaaaaa aaaaaaaaaa aaaaa. Aaaaaa aaaaaaaaa aaaaaa aaaaaaaa aaaaaaaa aaaaa aaaaaa aaaaaaa aaaaaaaaaaaa aaaaaaaaaaaaaa aaaaaaa aaaaaaaaaa aaaaa (Figure 1).

 **Graphs & Figures(Heading):**

70

60

* Font: 12 pt
* Bold
* Separated from the image, in text form.

50

40

30

20

10

0

Present study % (2014) S. Singh et al. % (2013)

D.J. Trivedi et al. %

(2010)

Bilodi et al. % (2002)

**Fig. 1:** aaaaaaaaaaaaa aaaaaaaaaaaaaaa aaaaaaaaaaaaaa aaaaaaaaa

**Guidelines for photographs:**

* 300 dpi
* JPEG,GIF

Aaaaaa aaaaaaaaa aaaaaa aaaaaaaa aaaaaaaa aaaaa aaaaaa aaaaaaa aaaaaaaaaaaa aaaaaaaaaaaaaa aaaaaaa aaaaaaaaaa aaaaa. Aaaaaa aaaaaaaaa aaaaaa aaaaaaaa aaaaaaaa aaaaa aaaaaa aaaaaaa aaaaaaaaaaaa aaaaaaaaaaaaaa aaaaaaa aaaaaaaaaa aaaaa. Aaaaaa aaaaaaaaa aaaaaa aaaaaaaa aaaaaaaa aaaaa aaaaaa aaaaaaa aaaaaaaaaaaa aaaaaaaaaaaaaa aaaaaaa aaaaaaaaaa aaaaa. Aaaaaa aaaaaaaaa aaaaaa aaaaaaaa aaaaaaaa aaaaa aaaaaa aaaaaaa aaaaaaaaaaaa aaaaaaaaaaaaaa aaaaaaa aaaaaaaaaa aaaaa (Figure 2).

Aaaaaa aaaaaaaaa aaaaaa aaaaaaaa aaaaaaaa aaaaa aaaaaa aaaaaaa aaaaaaaaaaaa aaaaaaaaaaaaaa aaaaaaa aaaaaaaaaa aaaaa. Aaaaaa aaaaaaaaa aaaaaa aaaaaaaa aaaaaaaa aaaaa aaaaaa aaaaaaa aaaaaaaaaaaa aaaaaaaaaaaaaa aaaaaaa aaaaaaaaaa aaaaa. Aaaaaa aaaaaaaaa aaaaaa aaaaaaaa aaaaaaaa aaaaa aaaaaa aaaaaaa aaaaaaaaaaaa aaaaaaaaaaaaaa aaaaaaa aaaaaaaaaa aaaaa. Aaaaaa aaaaaaaaa aaaaaa aaaaaaaa aaaaaaaa aaaaa aaaaaa aaaaaaa aaaaaaaaaaaa aaaaaaaaaaaaaa aaaaaaa aaaaaaaaaa aaaaa (Table 2).

DISCUSSION

Aaaaaa aaaaaaaaa aaaaaa aaaaaaaa aaaaaaaa aaaaa aaaaaa aaaaaaa aaaaaaaaaaaa aaaaaaaaaaaaaa aaaaaaa aaaaaaaaaa aaaaa. Aaaaaa aaaaaaaaa aaaaaa aaaaaaaa aaaaaaaa aaaaa aaaaaa aaaaaaa aaaaaaaaaaaa aaaaaaaaaaaaaa aaaaaaa aaaaaaaaaa aaaaa. Aaaaaa aaaaaaaaa aaaaaa aaaaaaaa aaaaaaaa aaaaa aaaaaa aaaaaaa aaaaaaaaaaaa aaaaaaaaaaaaaa aaaaaaa aaaaaaaaaa aaaaa.5 Aaaaaa aaaaaaaaa aaaaaa aaaaaaaa aaaaaaaa aaaaa aaaaaa aaaaaaa aaaaaaaaaaaa aaaaaaaaaaaaaa aaaaaaa aaaaaaaaaa aaaaa.6

Aaaaaa aaaaaaaaa aaaaaa aaaaaaaa aaaaaaaa aaaaa aaaaaa aaaaaaa aaaaaaaaaaaa aaaaaaaaaaaaaa aaaaaaa aaaaaaaaaa aaaaa. Aaaaaa aaaaaaaaa aaaaaa aaaaaaaa aaaaaaaa aaaaa aaaaaa aaaaaaa aaaaaaaaaaaa aaaaaaaaaaaaaa aaaaaaa aaaaaaaaaa aaaaa.7 Aaaaaa aaaaaaaaa aaaaaa aaaaaaaa aaaaaaaa aaaaa aaaaaa aaaaaaa aaaaaaaaaaaa aaaaaaaaaaaaaa aaaaaaa aaaaaaaaaa aaaaa. Aaaaaa aaaaaaaaa aaaaaa aaaaaaaa aaaaaaaa aaaaa aaaaaa aaaaaaa aaaaaaaaaaaa aaaaaaaaaaaaaa aaaaaaa aaaaaaaaaa aaaaa. Aaaaaa aaaaaaaaa aaaaaa aaaaaaaa aaaaaaaa aaaaa aaaaaa aaaaaaa aaaaaaaaaaaa aaaaaaaaaaaaaa aaaaaaa aaaaaaaaaa aaaaa.8

ACKNOWLEDGEMENTS

Aaaaaa aaaaaaaaa aaaaaa aaaaaaaa aaaaaaaa aaaaa aaaaaa aaaaaaa aaaaaaaaaaaa aaaaaaaaaaaaaa aaaaaaa aaaaaaaaaa aaaaa. Aaaaaa aaaaaaaaa aaaaaa aaaaaaaa aaaaaaaa aaaaa aaaaaa aaaaaaa aaaaaaaaaaaa aaaaaaaaaaaaaa aaaaaaa aaaaaaaaaa aaaaa. Aaaaaa aaaaaaaaa aaaaaa aaaaaaaa aaaaaaaa aaaaa aaaaaa aaaaaaa aaaaaaaaaaaa aaaaaaaaaaaaaa aaaaaaa aaaaaaaaaa aaaaa. Aaaaaa aaaaaaaaa aaaaaa aaaaaaaa aaaaaaaa aaaaa aaaaaa aaaaaaa aaaaaaaaaaaa aaaaaaaaaaaaaa aaaaaaa aaaaaaaaaa aaaaa.

**Authors’ contributions:** aaaaa aaaaa aaaaaaaaa aaaaaaaaaa aaaaaaaaa

DECLARATIONS

Funding: Aaaaaa aaaaaaaaa aaaaaa

Conflict of interest: Aaaaaa aaaaaaaaa aaaaaa

Ethical approval: Aaaaaa aaaaaaaaa aaaaaa

Consent for publication:

1. Garber A, Klein E, Bruce S, Sankoh S, Mohideen P. Metformin-glibenclamide versus metformin plus rosiglitazone in patients with type 2 diabetes inadequately controlled on metformin monotherapy. Diabetes Obes Metab 2006;8(2):156-63.

2. O'Brien C. Drug addiction and drug abuse. In: Brunton LB, Lazo JS, Parker KL, eds. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 11th ed. New York, NY: McGraw-Hill; 2005:607-29.

3. National Cancer Institute. Fact sheet: targeted cancer therapies, 2012. Available at http://www.cancer.gov/cancertopics/factsheet/Therapy/targeted#q1. Accessed 9 June 2014.

**General guidelines on references**

References should be numbered consecutively as they appear in the text. Reference citations in the text should be identified by numbers in superscript after the punctuation marks. All authors should be quoted for papers with up to six authors; for papers with more than six authors, the first six should be quoted followed by et al.

**Journal article:**

Leurs R, Church MK, Taglialatela M. H1‐antihistamines: inverse agonism, anti‐inflammatory actions and cardiac effects. Clinical & Experimental Allergy. 2002 Apr;32(4):489-98.

**Book chapter:**

Huff D. How to lie with statistics. 4th ed. London: Penguin, 1991, p.51.

**Website:**

National Cancer Institute. Fact sheet: targeted cancer therapies, 2012. Available at http://www.cancer.gov/cancertopics/factsheet/Therapy/targeted#q1. Accessed 9 June 2012.

REFERENCES